Clinical Trials

Breast Neoplasms

NCT07174336 2026-05-22

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07349069 2026-05-22

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer

5,500 enrolled

Breast Neoplasms

NCT07492641 2026-05-22

KANDELA-302

1,056 enrolled

HR+/HER2- Breast Cancer

NCT07029399 2026-05-19

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Phase 1 Recruiting

361 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

1,180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06380751 2026-05-15

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT07085767 2026-05-15

OPERA-02

1,000 enrolled

Breast Neoplasms

NCT05827081 2026-05-14

Adjuvant WIDER

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT06979596 2026-05-13

OMAHA-015

Phase 2 Recruiting

250 enrolled

Tumor-Agnostic

Neoplasms

NCT05774951 2026-05-08

CAMBRIA-1

4,300 enrolled

Breast Neoplasms

NCT06905301 2026-05-05

IMPULSE

Recruiting

240 enrolled

Breast Neoplasms

NCT06790693 2026-05-04

INAVO123

450 enrolled

Breast Neoplasms

NCT06998407 2026-05-04

AVZO-023-1001

380 enrolled

HR+/HER2- Breast Cancer

NCT04606446 2026-04-16

KAT6

Phase 2 Recruiting

320 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07389733 2026-04-03

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

180 enrolled

Advanced Unresectable or Metastatic Breast Cancer of Adults

NCT06072781 2026-04-02

RAMP 301

270 enrolled

Gynecologic

Low Grade Serous Ovarian Cancer

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Breast Neoplasms

NCT06016738 2026-03-13

OPERA-01

510 enrolled

Breast Neoplasms

NCT07024173 2026-01-26

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

240 enrolled

Breast Neoplasms

NCT06974929 2025-12-30

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

80 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06555068 2025-06-22

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

528 enrolled

Breast Neoplasms

NCT05952557 2025-06-19

CAMBRIA-2

5,500 enrolled

Breast Neoplasms

NCT04282031 2024-08-07

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

BreastOther solid neoplasm

224 enrolled

Advanced Solid Tumor

NCT05851014 2023-05-09

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

350 enrolled